Singapore - English - HSA (Health Sciences Authority)

qt instruments (s) pte ltd - yttrium (90) chloride - solution - 1850 mbq at calibration time and date - yttrium (90) chloride 1850 mbq at calibration time and date

European Union - English - EMA (European Medicines Agency)

ceft biopharma s.r.o. - ibritumomab tiuxetan - lymphoma, follicular - therapeutic radiopharmaceuticals - zevalin is indicated in adults.[90y]-radiolabelled zevalin is indicated as consolidation therapy after remission induction in previously untreated patients with follicular lymphoma. the benefit of zevalin following rituximab in combination with chemotherapy has not been established.[90y]-radiolabelled zevalin is indicated for the treatment of adult patients with rituximab relapsedorrefractory cd20+ follicular b-cell non-hodgkin's lymphoma (nhl).

Australia - English - Department of Health (Therapeutic Goods Administration)

innovative medical technologies pty ltd - 36169 - laser, erbium:yag - this is a laser used in surgical procedures that uses erbium/yttrium-aluminum garnet (yag) as the substrate.

Australia - English - Department of Health (Therapeutic Goods Administration)

endotherapeutics pty ltd - 36170 - surgical ho:yag laser system - a laser used in surgical procedures with holmium/yttrium-aluminium-garnet as the substrate.

United States - English - NLM (National Library of Medicine)

energique, inc. - american ginseng (unii: 8w75vcv53q) (american ginseng - unii:8w75vcv53q), ginkgo (unii: 19fuj2c58t) (ginkgo - unii:19fuj2c58t), arsenic triiodide (unii: 3029988o2t) (arsenic cation (3+) - unii:c96613f5av), avena sativa flowering top (unii: ma9cqj3f7f) (avena sativa flowering top - unii:ma9cqj3f7f), barium carbonate (unii: 6p669d8hq8) (barium cation - unii:v645272hln), phosphorus (unii: 27ylu75u4w) (phosphorus - unii:27ylu75u4w), silicon dioxide (unii: etj7z6xbu4) (silicon dioxide - unii:etj7z6xbu4), - for temporarily relieve mental sluggishness, confusion, weakness, lethargy, thirst, and frequent urination. **claims based upon traditional homeopathic practice, not accepted medical evidence. not fda evaluated. for temporarily relieve mental sluggishness, confusion, weakness, lethargy, thirst, and frequent urination. **claims based upon traditional homeopathic practice, not accepted medical evidence. not fda evaluated.

Canada - English - Health Canada

auro pharma inc - ibritumomab tiuxetan - kit - 3.2mg - ibritumomab tiuxetan 3.2mg - radioactive agents

United States - English - NLM (National Library of Medicine)

spectrum pharmaceuticals, inc. - ibritumomab tiuxetan (unii: 4q52c550xk) (ibritumomab tiuxetan - unii:4q52c550xk) - ibritumomab tiuxetan 1.6 mg in 1 ml - zevalin is indicated for the treatment of adult patients with relapsed or refractory, low-grade or follicular b-cell non-hodgkin's lymphoma (nhl). zevalin is indicated for the treatment of previously untreated follicular nhl in adult patients who achieve a partial or complete response to first-line chemotherapy. none. risk summary based on its radioactivity, y-90 zevalin may cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . immunoglobulins are known to cross the placenta. there are no available data on zevalin use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. advise women of childbearing potential to use adequate contraception for a minimum of twelve months. inform women who become pregnant while receiving zevalin of the potential fetal risks. the estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. all pregnancies have a background risk of birth defect, loss, or other

United States - English - NLM (National Library of Medicine)

acrotech biopharma inc - ibritumomab tiuxetan (unii: 4q52c550xk) (ibritumomab tiuxetan - unii:4q52c550xk) - zevalin is indicated for the treatment of adult patients with relapsed or refractory, low-grade or follicular b-cell non-hodgkin's lymphoma (nhl). zevalin is indicated for the treatment of previously untreated follicular nhl in adult patients who achieve a partial or complete response to first-line chemotherapy. none. risk summary based on its radioactivity, y-90 zevalin may cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)]  . immunoglobulins are known to cross the placenta. there are no available data on zevalin use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. advise women of childbearing potential to use adequate contraception for a minimum of twelve months. inform women who become pregnant while receiving zevalin of the potential fetal risks. the estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. all pregnancies have a background risk of birth defect, loss, or other

Australia - English - Department of Health (Therapeutic Goods Administration)

meditron pty ltd - 35940 - laser, nd:yag - a laser used in surgical procedures using a crystal comprising neodymium and yttrium-aluminium-garnet as the substrate.

Australia - English - Department of Health (Therapeutic Goods Administration)

boston scientific pty ltd - 61710 - manual-afterloading brachytherapy system storage container - for use in the administration of therasphere yttrium-90 glass microspheres only. the reusable administration accessory kit ensures optimal layout of the administration set and dose vial to facilitate monitoring of the infusion process and provides beta radiation shielding.